[
  {
    "ts": "2026-01-28T12:48:58+00:00",
    "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
    "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
    "url": "https://www.pharmaceutical-technology.com/news/cms-selects-next-batch-of-15-high-cost-medicines-for-third-negotiation-cycle/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "62d39b3a-c971-3378-8437-69454e7eb072",
      "content": {
        "id": "62d39b3a-c971-3378-8437-69454e7eb072",
        "contentType": "STORY",
        "title": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
        "description": "",
        "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
        "pubDate": "2026-01-28T12:48:58Z",
        "displayTime": "2026-01-28T12:48:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C1nJneUQiExdSmoCae_JSg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/63PlXOZomCP8u1XunFvtlg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/cms-selects-next-batch-of-15-high-cost-medicines-for-third-negotiation-cycle/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cms-selects-next-batch-15-124858672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "TAK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T12:04:00+00:00",
    "headline": "Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population",
    "summary": "The Global Glioma Market is focused on managing gliomas, aggressive brain tumors from glial cells. Glioblastoma Multiforme (GBM) is the deadliest type, characterized by rapid growth and invasiveness. Early diagnosis and treatment are crucial for improving patient outcomes. The market is driven by rising glioma cases, advancing cancer therapies, and enhanced diagnostic tools. Challenges include drug resistance, high treatment costs, and complex regulatory issues. Leading companies like Merck & Co",
    "url": "https://finance.yahoo.com/news/global-glioma-market-growth-driven-120400903.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "84028e1e-fe0c-3746-b3be-cdc043f031e1",
      "content": {
        "id": "84028e1e-fe0c-3746-b3be-cdc043f031e1",
        "contentType": "STORY",
        "title": "Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population",
        "description": "",
        "summary": "The Global Glioma Market is focused on managing gliomas, aggressive brain tumors from glial cells. Glioblastoma Multiforme (GBM) is the deadliest type, characterized by rapid growth and invasiveness. Early diagnosis and treatment are crucial for improving patient outcomes. The market is driven by rising glioma cases, advancing cancer therapies, and enhanced diagnostic tools. Challenges include drug resistance, high treatment costs, and complex regulatory issues. Leading companies like Merck & Co",
        "pubDate": "2026-01-28T12:04:00Z",
        "displayTime": "2026-01-28T12:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/global-glioma-market-growth-driven-120400903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/global-glioma-market-growth-driven-120400903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T13:30:00+00:00",
    "headline": "TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026",
    "summary": "TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will highlight practical, scalable approaches to advancing more efficient, patient-centered clinical trials across the research lifecycle at SCOPE Summit 2026, taking place February 2-5 in Orlando, Florida.",
    "url": "https://finance.yahoo.com/news/transcelerate-biopharma-showcases-approaches-advancing-133000205.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "a4a68708-122d-314f-b901-b231171e04f6",
      "content": {
        "id": "a4a68708-122d-314f-b901-b231171e04f6",
        "contentType": "STORY",
        "title": "TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026",
        "description": "",
        "summary": "TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will highlight practical, scalable approaches to advancing more efficient, patient-centered clinical trials across the research lifecycle at SCOPE Summit 2026, taking place February 2-5 in Orlando, Florida.",
        "pubDate": "2026-01-28T13:30:00Z",
        "displayTime": "2026-01-28T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/8f1b12e1f864d34950521bd9e92e0b08",
          "originalWidth": 400,
          "originalHeight": 109,
          "caption": "TransCelerate BioPharma (PRNewsfoto/TransCelerate BioPharma)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vVswb4M33A3mRhb6Ae6Gog--~B/aD0xMDk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8f1b12e1f864d34950521bd9e92e0b08.cf.webp",
              "width": 400,
              "height": 109,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rgzb5Fajr8TOTPYyKl6rFQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8f1b12e1f864d34950521bd9e92e0b08.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/transcelerate-biopharma-showcases-approaches-advancing-133000205.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/transcelerate-biopharma-showcases-approaches-advancing-133000205.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T13:18:59+00:00",
    "headline": "Pfizer Reshapes Portfolio As ViiV Exit Meets White House Pricing Deal",
    "summary": "Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic areas. The company has reached a significant agreement with the White House that trades tariff relief for reduced drug pricing in the U.S. Pfizer is advancing late-stage drugs in its pipeline and has signed a non-exclusive licensing deal with Novavax for Matrix-M vaccine adjuvant technology. Pfizer (NYSE:PFE) is making several moves at once, shifting away from the ViiV...",
    "url": "https://finance.yahoo.com/news/pfizer-reshapes-portfolio-viiv-exit-131859459.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "9363af32-caf6-339e-81e9-80d4debf3e3e",
      "content": {
        "id": "9363af32-caf6-339e-81e9-80d4debf3e3e",
        "contentType": "STORY",
        "title": "Pfizer Reshapes Portfolio As ViiV Exit Meets White House Pricing Deal",
        "description": "",
        "summary": "Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic areas. The company has reached a significant agreement with the White House that trades tariff relief for reduced drug pricing in the U.S. Pfizer is advancing late-stage drugs in its pipeline and has signed a non-exclusive licensing deal with Novavax for Matrix-M vaccine adjuvant technology. Pfizer (NYSE:PFE) is making several moves at once, shifting away from the ViiV...",
        "pubDate": "2026-01-28T13:18:59Z",
        "displayTime": "2026-01-28T13:18:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-reshapes-portfolio-viiv-exit-131859459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-reshapes-portfolio-viiv-exit-131859459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVAX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T08:00:00+00:00",
    "headline": "Has Novavax cracked the code for survival in the vaccine arena?",
    "summary": "The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.",
    "url": "https://www.pharmavoice.com/news/novavax-vaccine-rfkjr-hhs-fda-pfizer/810662/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "78016802-e39b-3e5d-8edb-e9d5274541f0",
      "content": {
        "id": "78016802-e39b-3e5d-8edb-e9d5274541f0",
        "contentType": "STORY",
        "title": "Has Novavax cracked the code for survival in the vaccine arena?",
        "description": "",
        "summary": "The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.",
        "pubDate": "2026-01-28T08:00:00Z",
        "displayTime": "2026-01-28T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/c0010768e24b33437637450714d2536b",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Syringes with a dose of Novavax's COVID-19 vaccine are prepared for use at a vaccination center on February 28, 2022 in Berlin, Germany.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8pf_N_oPtF.y0_4OYLvj1w--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/c0010768e24b33437637450714d2536b.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wxyNGLqOBAk8FN2XcjOcHA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/c0010768e24b33437637450714d2536b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/novavax-vaccine-rfkjr-hhs-fda-pfizer/810662/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novavax-cracked-code-survival-vaccine-080000548.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVAX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]